Verastem

The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline
The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline
Endpoints
duvelisib
Verastem
AbbVie
Flag link:
Verastem Oncology announces preliminary data from investigator-initiated study highlighting clinical activity of RAF/MEK and FAK combination in KRAS mutant tumors
Verastem Oncology announces preliminary data from investigator-initiated study highlighting clinical activity of RAF/MEK and FAK combination in KRAS mutant tumors
Pharmaceutical Business Review
Verastem
clinical trials
VS-6766
solid tumors
AACR
Flag link:
Verastem Oncology Sees Strategic Realignment To Reduce Its Operating Expenses By About 40% For 2020
Verastem Oncology Sees Strategic Realignment To Reduce Its Operating Expenses By About 40% For 2020
Reuters
Verastem
realignment
layoffs
Flag link:
Verastem pens KRAS-focused drug licensing deal with Chugai
Verastem pens KRAS-focused drug licensing deal with Chugai
Fierce Biotech
Verastem
KRAS
cancer
Chugai
Flag link:
Forrester steps down as CEO of Verastem
Forrester steps down as CEO of Verastem
Fierce Biotech
Verastem
Robert Forrester
Pharma CEOs
Flag link:
Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success
Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success
Endpoints
Verastem
AbbVie
Infinity Pharmaceuticals
duvelisib
Flag link:
At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA
At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA
Xconomy
Verastem
Infinity Pharma
FDA
duvelisib
CLL
follicular lymphoma
small lymphocytic lymphoma
Flag link:
#ASH17: Verastem’s AbbVie castoff is headed for the FDA — even after missing overall survival goal
#ASH17: Verastem’s AbbVie castoff is headed for the FDA — even after missing overall survival goal
Endpoints
ASH17
AbbVie
Verastem
FDA
duvelisib
chronic lymphocytic leukemia
Flag link:
Verastem moves closer to US filing for blood cancer drug
Verastem moves closer to US filing for blood cancer drug
BioPharma Dive
Verastem
duvelisib
chronic lymphocytic leukemia
small lymphocytic lymphoma
Flag link:
Verastem bet on blood cancer drug pays off with trial success
Verastem bet on blood cancer drug pays off with trial success
BioPharma Dive
Verastem
clinical trials
duvelisib
Flag link:
On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders
On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders
Endpoints
duvelisib
Infinity Pharmaceuticals
Verastem
Flag link:
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Yahoo
Merck
Pfizer
Verastem
ovarian cancer
clinical trials
avelumab
VS-6063
Flag link:
The top 10 biopharma pipeline disasters of 2015
The top 10 biopharma pipeline disasters of 2015
Fierce Biotech
Eli Lilly
GSK
AstraZeneca
Shire
Celladon
Takeda
Merck
Roche
Verastem
evacetrapib
Breo Ellipta
brodalumab
selumetinib
SHP625
Mydicar
Alisertib
suggammadex
sembragiline
Defactinib
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
Verastem concedes lead drug flopped in PhII mesothelioma study
Verastem concedes lead drug flopped in PhII mesothelioma study
Fierce Biotech
Verastem
mesothelioma
Defactinib
clinical trials
Flag link:
After two deaths, Verastem defends safety of experimental cancer drug
After two deaths, Verastem defends safety of experimental cancer drug
Bizjournals.com
Verastem
VS-6063
non-small cell lung cancer
Flag link:
Large U.S. cancer trial to match genetic glitches to targeted drugs
Large U.S. cancer trial to match genetic glitches to targeted drugs
Yahoo/Reuters
clinical trials
Pfizer
Xalkori
Boehringer Ingelheim
Gilotrif
Roche
Kadcyla
AZD9291
AstraZeneca
VS-6063
Verastem
personalized medicine
Flag link:
Verastem Inc.'s Upcoming Catalysts
Verastem Inc.'s Upcoming Catalysts
Motley Fool
Verastem
Flag link:
Three Biotechs That Could Double
Three Biotechs That Could Double
Yahoo/Street Authority
Verastem
Versartis
Threshold Pharmaceuticals
Flag link:
Verastem publishes data on targeting mesothelioma cancer stem cells
Verastem publishes data on targeting mesothelioma cancer stem cells
The Fly on the Wall
Verastem
mesothelioma
stem cells
Flag link:

Pages